Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 263

Sort by

Sort Order Select

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis

Blood blood.2024025681.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Salma B. Abdelbaky, Brian Giacopelli, Kari G. Rabe, Kyoko Yamaguchi, Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, Sochilt Brown, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes

Blood (2024) 143 (17): 1752–1757.

https://doi.org/10.1182/blood.2023022180

Published: 2024

Includes: Supplemental data

Journal Articles

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Côme Bommier, Emanuele Zucca, Sylvie Chevret, Annarita Conconi, Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Catherine Thieblemont, Jérôme Lambert

Blood (2024) 143 (5): 422–428.

https://doi.org/10.1182/blood.2023020984

Published: 2024

Includes: Supplemental data

Journal Articles

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Blood (2023) 142 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2023-182266

Published: 2023

Journal Articles

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Raphael Mwangi, Grzegorz S. Nowakowski, Carla Casulo, Dai Chihara, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Peter Martin, Yucai Wang, Timothy J. McDonnell, Andrew L. Feldman, David L Jaye, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2023-174715

Published: 2023

Journal Articles

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Amber Koehler, Brie N. Noble, Timothy G. Call, Sameer A. Parikh, Tait D. Shanafelt, Mazie Tsang, Côme Bommier, Kari G. Rabe, Christopher Strouse, Carrie Thompson, Paul J. Hampel, Kathleen Yost, Melissa C. Larson, Susan L. Slager, Brian K. Link, James R. Cerhan, Amylou Constance Dueck

Blood (2023) 142 (Supplement 1): 498.

https://doi.org/10.1182/blood-2023-187268

Published: 2023

Journal Articles

DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma

Melissa A. Hopper, Abigail R. Dropik, Janek S. Walker, Joseph P. Novak, Miranda S. Laverty, Michelle Manske, Xiaosheng Wu, Kerstin Wenzl, Jordan Edward Krull, Vivekananda Sarangi, Matthew J. Maurer, Thomas M. Habermann, Brian K. Link, Lisa M. Rimsza, Thomas E. Witzig, Stephen M Ansell, James R. Cerhan, Dragan Jevremovic, Anne J. Novak

Blood (2023) 142 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2023-180232

Published: 2023

Journal Articles

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Blood (2023) 142 (Supplement 1): 2770.

https://doi.org/10.1182/blood-2023-180949

Published: 2023

Journal Articles

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

Jonathan R Day, Melissa C. Larson, Carla Casulo, Urshila Durani, Yucai Wang, Dai Chihara, Loretta J. Nastoupil, Brad S. Kahl, Peter Martin, Izidore S. Lossos, Jason T. Romancik, Amy Ayers, Richard Burack, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Brian K. Link

Blood (2023) 142 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2023-179650

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

The FLIPI24 Prognostic Model Identifies Poor Outcomes in Non-Immunochemotherapy Treated Patients with Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2023-186684

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

Journal Articles

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Blood (2023) 142 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2023-187056

Published: 2023

Journal Articles

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Rosalie Griffin, Aswin Sekar, Sameer A. Parikh, Giulio Genovese, Dennis P. Robinson, Aaron D. Norman, Janet E. Olson, Kari G. Rabe, Nicholas J. Boddicker, Paul J. Hampel, Neil E. Kay, Timothy G. Call, James R. Cerhan, Esteban Braggio, Curtis A. Hanson, Caline M. Vachon, Tait D. Shanafelt, Benjamin L. Ebert, Susan L. Slager

Blood (2023) 142 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2023-184696

Published: 2023

Journal Articles

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2023-180318

Published: 2023

Journal Articles

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Jacqueline F. Wang, Jihao Zhou, Steven R Hwang, Catherine S Diefenbach, Jia Ruan, Peter Martin, Jonas Paludo, Javier L. Munoz, Stephen M Ansell, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski, Yucai Wang

Blood (2023) 142 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2023-179611

Published: 2023

Journal Articles

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Blood (2023) 142 (Supplement 1): 67.

https://doi.org/10.1182/blood-2023-190316

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Umar Farooq, Jason T. Romancik, Jonathan W. Friedberg, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Dai Chihara, Andrew L. Feldman, Sergei Syrbu, David L Jaye, Elliot Cahn, Thomas M. Habermann, Brian K. Link, James R. Cerhan, Christopher R. Flowers, Loretta J. Nastoupil, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2023-187350

Published: 2023

Journal Articles

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3761.

https://doi.org/10.1182/blood-2023-188382

Published: 2023

NARROW

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO Cohort Study analysis

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes

Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma

Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups

Patterns of Care and Prognostic Modeling Following Follicular Lymphoma Transformation to Aggressive B-Cell Lymphoma: An Analysis from the LEO Consortium

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

The FLIPI24 Prognostic Model Identifies Poor Outcomes in Non-Immunochemotherapy Treated Patients with Follicular Lymphoma

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study

A National Cancer Database Study of Survival Trends in Patients with Mantle Cell Lymphoma Stratified By Age Group

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only